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Vav is a member of a family of oncogene proteins that share an approximately 250-amino-acid motif called
a Dbl homology domain. Paradoxically, Dbl itself and other proteins containing a Dbl domain catalyze
GTP-GDP exchange for Rho family proteins, whereas Vav has been reported to catalyze GTP-GDP exchange
for Ras proteins. We present Saccharomyces cerevisiae genetic data, in vitro biochemical data, and animal cell
biological data indicating that Vav is a guanine nucleotide exchange factor for Rho-related proteins, but in
similar genetic and biochemical experiments we fail to find evidence that Vav is a guanine nucleotide exchange
factor for Ras. Further, we present data indicating that the Lck kinase activates the guanine nucleotide
exchange factor and transforming activity of Vav.
vav is a proto-oncogene expressed primarily, if not exclu-
sively, in hematopoietic cells (22, 23). Recent studies have
yielded conflicting results concerning activities associated with
Vav. Several reports suggest that Vav is a guanine nucleotide
exchange factor (GEF) capable of converting Ras to its active
GTP-bound state (14–16). Other reports conclude that Vav is
not a Ras GEF and provide evidence that Ras and Vav coop-
erate in the activation of mitogenic pathways (5, 24). While
Vav is not structurally related to other well-characterized Ras
GEFs, it contains a Dbl homology domain and SH2 and SH3
domains (1, 9, 29). The Dbl protein and several structurally
related molecules are known to regulate CDC42Hs (or mem-
bers of the Rho family) by acting as GEFs (18, 19).
While several reports indicate that Vav is a GEF for Ras,
several other reports provide circumstantial evidence suggest-
ing that Vav is a GEF for Rho-related proteins but not for Ras
(14, 24). Vav-transformed cells closely resemble Dbl-trans-
formed cells, exhibiting phenotypes distinct from those of Ras-
transformed cells (5, 24). First, Vav- and Dbl-transformed cells
exhibit well-developed stress fibers and focal adhesions, which
are lacking in Ras-transformed cells (24). Second, in contrast
to Ras transformation, Vav transformation and Dbl transfor-
mation fail to activate transcription from Ras-responsive ele-
ments (24). Third, in contrast to Ras transformation or Ras
GEF transformation, Vav- or Dbl-transformed cells do not
exhibit an increase in cellular Ras GTP levels (24). Those
investigators concluded that Vav transformation is not a con-
sequence of Ras activation, but they speculated that Vav trans-
formation, like Dbl transformation, is a consequence of acti-
vation of Rho family members. Vav has a Dbl homology
domain, and, by analogy with the Dbl protein, it has been
postulated to have GEF activity towards the Rho family of
GTPases (19, 24). The morphology of Vav-transformed cells is
similar to that of Rho-transformed cells (25, 36). This obser-
vation is consistent with the role of Vav as an activator of
Rho-related proteins involved in cytoskeletal reorganization.
In the present study, we provide direct evidence for the role of
Vav as a GEF for Rho family members.
The Lck tyrosine kinase plays a role in T-cell activation,
which is triggered by receptor ligation (26, 33, 44). Previous
reports demonstrate that cross-linking of B- or T-cell antigen
receptors results in the rapid tyrosine phosphorylation of a
number of proteins, including Vav (26, 33, 43, 44). Further, the
Vav protein can serve as a substrate for Lck kinase in vitro,
suggesting that Lck kinase may play a critical role in T-cell
signaling by activating Vav signaling (14, 15, 43). Using Sac-
charomyces cerevisiae genetic, biochemical, and biological as-
says, we tested whether Lck is also involved in the Vav-medi-
ated signaling pathway of Rho-related GTPases. In this paper,
we demonstrate that Lck kinase is involved in the Vav signaling
pathway by modulating the GEF activity of Vav for Rho family
proteins. These are the first data concerning the regulation of
the activity of Dbl-related proteins.
MATERIALS AND METHODS
Construction of yeast expression plasmids. The pAD4-Vav(wt) plasmid was
constructed by subcloning the SpeI-SalI fragment encoding full-length mouse
Vav from the vav clone pMB24 (9) into the HindIII-SalI site of the yeast
expression vector pAD4 (47). pAD4-Vav(onc) was made by subcloning the
NruI-SalI fragment of vav from pMB24 into HindIII-SalI-digested pAD4. pAD4-
Vav(DH) was made by digesting pAD4-Vav(onc) with NcoI and HindIII and
self-ligating the 9.6-kb fragment. To construct the YEp24ADH-Lck plasmid, a
1.5-kb StuI fragment encoding mouse Lck was cut out from m-lck clone NT18
(30) and subcloned into the SalI site of YEp24ADH. YEp24ADH was con-
structed by subcloning the BamHI-SalI ADH promoter fragment of pAD4 into
the BamHI-SalI-digested YEp24 vector (40). YEp103-cdc24 (8) was provided by
Alan Bender. Plasmid pRS315(CDC42Sc) (50) was provided by Douglas John-
son.
The 2.4-kb NruI-SspI Vav fragment from pMB24 was subcloned into the SmaI
site of pAD4caax to create plasmid pVav(caax). pAD4caax was created by
inserting an oligonucleotide encoding the CAAX box of H-ras into SalI-SacI-
digested pAD4 (37).
Molecular constructs. Molecular constructs encoding mouse proto-Vav
(pJC11), N-terminally truncated and transforming DVav (JC12), proto-Dbl
(pZIP-pDbl), N-terminally truncated and transforming Dbl (pZIP-Dbl), consti-
tutively activated human RhoA [pZIP-RhoA(63L)], and wild-type (pLXSN-Lck)
and constitutively activated [pLXSN-Lck(505F)] Lck have been described pre-
viously (24, 46).
Yeast strains and complementation assay. The temperature-sensitive yeast
strain ABY147 (MATa cdc24-4 ura3 leu2 his3) was kindly provided by Alan
Bender (2). Strain ABY178 (also referred to as DJTD2-16D) (MATa cdc42-1
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ura3 leu2 trp1 his4) was kindly provided by Alan Bender (21). Yeast transfor-
mations were performed by the lithium acetate method with the modification
that 25 mM dithiothreitol was included in the transformation buffers (40).
Complementation assays were performed as described in the legend of Fig. 2.
Preparation of Vav and small GTPases. The vav cDNA was subcloned into the
bacterial expression vector pRSET-B (Invitrogen) by using PCR-amplified cop-
ies of the vav cDNA flanked by restriction endonuclease sites (XhoI and
HindIII). The fragments used corresponded to vav codons 170 through 481 and
170 through 845. Plasmids constructed were transformed into Escherichia coli
BL21 (DE3). Induction and purification of the His-tagged fusion proteins were
performed essentially as described previously (35). The final concentration and
purity of the proteins were determined by sodium dodecyl sulfate (SDS)-poly-
acrylamide gel electrophoresis (PAGE). The apparent molecular sizes of the
His6-tagged Vav proteins are 35 and 75 kDa. Glutathione-agarose beads were
incubated with E. coli extract of the glutathione S-transferase (GST)-RhoA,
GST-Rac1, GST-CDC42Hs, GST-Ran, or GST–H-Ras expression systems for
1 h and then extensively washed in buffer A (50 mM Tris-HCl [pH 7.5], 5 mM
MgCl2, 20 mM KCl, 1 mM dithiothreitol) containing 1% Triton X-100 to remove
all unbound materials. Beads bound with proteins were then incubated in a
solution containing 50 mM Tris-HCl (pH 8.0), 5 mM MgCl2, and 10 mM gluta-
thione, and the resulting dissociated proteins were dialyzed overnight against 300
volumes of buffer A. GST fusion protein expression systems for RhoA, Rac1, and
CDC42Hs were kindly provided by Gary Bokoch. Expression vector for GST-
Ran was a generous gift from Linda Van Aelst. A restriction fragment of
wild-type H-Ras (BamHI and EcoRI) was subcloned into pGEX-2T (Pharmacia)
to generate the fusion expression vector for GST–H-Ras.
In vitro binding of Vav and small GTPases. Nickel-agarose or His6-tagged-
Vav-coated nickel-agarose beads (50 pmol) were resuspended in 250 ml of buffer
A containing 5 mM imidazole and 500 mg of bovine serum albumin (BSA) per
ml; then, 500 pmol of GST-GTPases (RhoA, Rac1, CDC42Hs, Ran, and H-Ras)
in their nucleotide-free state, GDP-bound state, or GTP-bound state was added,
and the mixture was incubated with shaking at room temperature for 1 h. After
the incubation period, the beads were pelleted and washed five times in a
solution containing 50 mM Tris-HCl (pH 7.5), 1% Triton X-100, 0.5 M NaCl,
and 60 mM imidazole. Precipitated proteins were separated by SDS-PAGE and
electrophoretically transferred to nitrocellulose membrane. GST fusion protein
was detected by blotting with anti-GST antibody (Santa Cruz Biotechnology) and
reagents from the Immun-Lite chemiluminescent blotting kit (Bio-Rad, Rich-
mond, Calif.). In control experiments GST-CDC25 failed to bind Rho, Rac, or
CDC42 under conditions where GST-Vav(L) bound significant amounts of these
GTPases.
In vitro GEF activity of Vav directed toward various GTPases. GST-GTPase
proteins were loaded with [3H]GDP (10 Ci/mmol; DuPont) as described previ-
ously (11). Forty picomoles of [3H]GDP-GST-GTPase was incubated with 10
pmol of His-tagged Vav alone or His-tagged Vav phosphorylated by Lck kinase
in 200 ml of buffer A containing 1 mM GTP. After 15 min of incubation at room
temperature, 50 ml of reaction product was removed and binding of [3H]GDP to
GST-GTPase protein was quantified by filtration on nitrocellulose filters and
liquid scintillation counting as previously described (4).
Phosphorylation of Vav by Lck kinase. Five micrograms of His6-Vav protein
bound to nickel-agarose beads was washed with kinase buffer (10 mM HEPES
[pH 7.0], 10 mM ATP, 12 mM MgCl2) and incubated with 5 ng of recombinant
Lck tyrosine kinase for 30 min at 378C. Phosphorylated Vav protein bound to
nickel-agarose beads was then washed with either buffer A containing 5 mM
imidazole and 500 mg of BSA per ml for in vitro binding experiments or with
buffer A for GEF assay.
Cell culture and transformation assays. NIH 3T3 cells were grown in Dul-
becco’s modified Eagle’s medium supplemented with 10% calf serum. DNA
transfections were done by the calcium phosphate precipitation technique as
described previously (7). Cells were transfected with plasmid constructs encoding
the indicated proteins at 1 mg per dish for proto-Vav, DVav, proto-Dbl, and
RhoA(63L) and at 10 ng per dish for DDbl alone or were cotransfected with 500
ng of c-Lck or 100 ng of activated Lck(505F) per dish. Transformed foci were
quantitated after 14 days. Transfected cultures were stained with 0.4% crystal
violet to better visualize transformed foci.
Transfection and immunofluorescence. Rat embryo fibroblast (REF-52) cells
were grown to 80% confluence in Dulbecco’s modified Eagle’s medium with 10%
fetal bovine serum and transfected as previously described (13) with 1 mg of total
DNA per 60-mm-diameter dish for 16 h. After 16 h, cells were prepared for
immunofluorescence as previously described (41). Tagged V12Cdc42, V12Rac1,
and oncogenic Vav were visualized with anti-T7 antibody (Novagen) and rho-
damine-conjugated goat anti-mouse secondary antibody (Molecular Probes).
Filamentous actin was visualized with fluorescein isothiocyanate-phalloidin. Flu-
orescent images were photographed on a Zeiss Axiophot microscope using a 633
oil-immersion lens and Kodak P3200 Tmax film. Plasmid construction for this
purpose was done as follows: CDC42Hs(Val12), VRac1(Val12), and oncogenic
Vav were amplified by PCR from cDNA clones (generous gifts of Alan Hall) and
subcloned as an XbaI-SalI fragment in pCGT. pCGT is derived from pCGN (42)
with a replacement of the Lerner epitope by the T7 epitope (generous gift from
Angus Wilson, Cold Spring Harbor Laboratory).
Jnk assays. Jun nuclear kinase (Jnk) assays were done as previously described
(45). Briefly, transiently transfected COS cells were lysed in modified radioim-
munoprecipitation assay buffer. Lysates containing approximately 30 mg of pro-
tein were incubated with 1 to 5 mg of GST–c-Jun(1-79) substrate in a kinase
assay. Proteins were then separated by SDS-PAGE, and the phosphorylation of
the substrate was observed after autoradiography.
Other materials and methods. Oligonucleotides were purchased from the
University of Southern California Microchemical Core Laboratory. E. coli trans-
formations were performed by electroporation as described by the manufacturer
(Bio-Rad). Yeast strains were grown in yeast extract-peptone-dextrose medium
or synthetic complete (SC) medium (40). E. coli strains were grown in Luria-
Bertani medium containing 100 mg of ampicillin per ml. DNA sequencing was
performed by the method of Sanger et al. (39) with a Sequenase version 2.0 kit
from United States Biochemical Corp., Cleveland, Ohio.
RESULTS
Vav suppresses a cdc24 temperature-sensitive defect in S.
cerevisiae. Because Vav contains a domain structurally related
to the GEF domain of Dbl and other Dbl family proteins, we
predicted that Vav might be a positive regulator of CDC42,
Rho, or Rac molecules by functioning as a GEF. The yeast S.
cerevisiae CDC42 gene product is homologous to the verte-
brate CDC42Hs protein. The yeast CDC42-GTPase is regu-
lated by a Dbl-related GEF encoded by CDC24. Temperature-
sensitive mutations in the yeast genes cdc24 and cdc42 result in
similar lethal phenotypes at the restrictive temperature. We
tested whether Vav can suppress the temperature-sensitive
defect of a cdc24 strain of yeast. The biological activity of Vav
has been reported to be activated by an N-terminal deletion or
by Lck phosphorylation of the full-length Vav (14, 23). Con-
sequently, we tested full-length Vav and fragments of Vav (Fig.
1) for suppression of the cdc24 temperature-sensitive defect.
From these experiments we have obtained genetic data sug-
gesting that Vav functions like Dbl, regulating a CDC42 family
member.
We find that oncogenic Vav (lacking the N-terminal 66
amino acids) can partially suppress the loss of the S. cerevisiae
Dbl homolog CDC24 (6, 12) (Fig. 1 and 2a). This suppression
is due to the Dbl homology domain of Vav as judged by the
ability of residues 66 through 566 of Vav (encompassing the
Dbl homology domain) to complement the loss of CDC24
function (Fig. 1 and 2a). In contrast, full-length Vav (Fig. 1 and
2a) as well as a fragment of Vav lacking a portion of the Dbl
homology domain (data not shown) failed to suppress the loss
of CDC24 function. These results suggest that the Dbl homol-
ogy domain of Vav, like the yeast CDC24-GEF, can activate
the endogenous yeast CDC42-GTPase. In support of this sug-
gestion, Vav failed to suppress the loss of CDC42 function in
yeast, indicating that Vav does not function downstream of
CDC42 (Fig. 2c). Further, if Vav was a GEF for Ras proteins
as previously suggested (14–16), we predicted that Vav should
suppress the loss of the yeast Ras-specific GEF encoded by
CDC25. When a cdc25ts mutant strain was used, all fragments
FIG. 1. Schematic representation of the fragments of Vav used for these
studies. Full-length Vav encodes a protein of 845 amino acids including a domain
homologous to the Dbl protein (DBL), a plekstrin homology (PH) domain, and
SH2 and SH3 domains. Full-length Vav or the indicated fragments of Vav were
cloned into the yeast expression vector pAD4 (32), into the E. coli expression
vector pRSET (Invitrogen) for the production of His6-tagged fusion proteins, or
into the animal cell expression vector pCGT (42).
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of Vav described here (Fig. 1) failed to complement the loss of
CDC25 function (data not shown).
Previous reports have proposed that the Lck tyrosine kinase
is a positive regulator of Vav function (14). We examined
whether coexpression of full-length Vav and Lck affected the
ability of Vav to complement yeast CDC24 function. Although
full-length Vav failed to suppress the cdc24 temperature-sen-
sitive defect, coexpression of full-length Vav and Lck comple-
mented the loss of CDC24 function (Fig. 2b). Further, Lck
enhanced the ability of oncogenic Vav to suppress the loss of
CDC24 function (data not shown). These results show that
Vav’s ability to activate the yeast CDC42-GTPase is enhanced
either by an N-terminal deletion or by Lck-phosphorylation of
Vav.
Vav preferentially binds to the nucleotide-free form of
CDC42-related GTPases. We examined whether Vav could
bind to various GTPases in a manner similar to that reported
for other GEFs, such as Dbl, SOS, and CDC25 (32). A bio-
chemical hallmark of GEFs is their ability to bind significantly
more tightly to the nucleotide-free form of their corresponding
GTPases than to their GTPases when complexed to guanine
nucleotides (32). His6-tagged fusions of fragments of Vav (res-
idues 170 through 845 [Vav(L)] and residues 170 through 481
encompassing the Dbl homology domain [Vav(DH)] (Fig. 1)
were purified from E. coli expression systems. The fragments
of Vav bound to Ni-agarose were incubated with purified
GST fusions of GTPases in their nucleotide-free state, GDP-
bound state, or GTP-bound state. After incubation, the Ni-
agarose beads were washed and the resulting pellets were
analyzed by immunoblotting with antibodies specific for GST.
GST-CDC42Hs, GST-Rac1, and GST-RhoA were initially
tested for precipitation by Ni-agarose bound with His6-Vav(L),
His6-Vav(DH), or Ni-agarose alone. As seen in Fig. 3,
CDC42Hs and Rac1 in their nucleotide-free state bound well
to both His6-Vav(L) and His6-Vav(DH). In contrast, GDP-
bound and GTP-bound forms of CDC42Hs and Rac1 bound to
the fragments of Vav only weakly compared to the nucleotide-
free proteins (Fig. 3). In similar binding reactions, His6-Vav(L)
bound equally well to nucleotide-free RhoA, GDP-bound
RhoA, or GTP-bound RhoA (Fig. 3).
Previous reports have indicated that the Lck tyrosine kinase
positively regulates Vav signaling (14). We tested whether
phosphorylation of His6-Vav(L) by recombinant Lck altered
the former’s ability to bind to CDC42Hs, Rac1, and RhoA.
FIG. 2. Vav can suppress the loss of CDC24 function in S. cerevisiae. (a) The S. cerevisiae cdc24 temperature-sensitive strain ABY147 (2) was cotransformed with
pAD4-based vectors containing fragments of Vav (Fig. 1) together with a YEp103-based vector. Transformants were selected by plating onto SC media lacking leucine
(for selection of the pAD4-based vectors) or lacking uracil (for selection of the YEp103-based vectors). For a positive control, the strain ABY147 was cotransformed
with pAD4 (vector 2) and a YEp103-based vector containing the wild-type yeast CDC24. Four independent transformants from each of the transformations were
patched onto SC2Leu,2Ura plates and incubated for 2 days. The resulting master plate was replica plated onto two SC2Leu,2Ura plates; one plate was incubated at 358C
(the nonpermissive temperature) for 3 days, while the other plate was incubated at 288C (the permissive temperature) for 3 days. (b) The S. cerevisiae cdc24
temperature-sensitive strain ABY147 (2) was cotransformed with a full-length (wt) Vav-pAD4 expression vector together with a YEp24-based vector expressing the
mouse Lck cDNA under the control of the yeast ADH promoter. Also, the Lck expression vector was cotransformed with the empty vector pAD4. For a positive control,
the strain ABY147 was cotransformed with a yeast YEp103-CDC24 expression vector together with vector pAD4 (vector 2). Transformants for each of these
cotransformations were patched onto SC2Leu,2Ura plates. For a negative control, strain ABY147 was cotransformed with vectors pAD4 (vector 2) and YEp24 (vector
1). The resulting master plate was replica plated onto two SC2Leu,2Ura plates; one plate was incubated at 358C for 3 days while the other was incubated at 288C for
3 days. (c) The S. cerevisiae CDC42 temperature-sensitive strain ABY178 was transformed with pAD4-based vectors expressing oncogenic Vav, the Dbl homology
domain of Vav, or oncogenic Vav fused to a CAAX box. ABY178 cells transformed with a CDC42-expressing vector, pRS315(CDC42Sc), were used as positive controls.
Cells transformed with pAD4 (vector 2) and pAD5 (vector 3) were used as negative controls. Two independent transformants from each transformation were patched
onto SC2Leu plates and incubated at 288C for 2 days. The resulting master plate was replica plated onto two SC2Leu plates. One plate was incubated at 358C and the
other at 288C for 3 days.
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His6-Vav(L) complexed to Ni-agarose beads was phosphory-
lated by incubation with recombinant Lck kinase and ATP for
30 min. At completion of the kinase reaction, the Lck kinase
was removed by extensive washing of the Ni-agarose beads.
The phosphorylated His6-Vav(L) was then incubated with
GST-CDC42Hs, GST-Rac1, or GST-RhoA in their nucleo-
tide-free, GDP-bound, or GTP-bound states. After washing of
the Ni-agarose beads, the resulting pellets were analyzed by
immunoblotting with anti-GST antibodies. As seen in Fig. 3,
CDC42Hs and RhoA in their nucleotide-free forms bound well
to the Lck-phosphorylated Vav(L). In contrast, Lck-phosphor-
ylated Vav(L) bound significantly less well to the GDP- and
GTP-bound versions of each GTPase (Fig. 3). Similarly, nu-
cleotide-free Rac1, but not nucleotide-bound Rac1, bound well
to the Lck-phosphorylated Vav(L) (data not shown). The pref-
erential binding of these GTPases to Vav when in their nucle-
otide-free state is consistent with the suggestion based on the
yeast genetic data presented above that Vav is a GEF for
Rho-related molecules and that Lck phosphorylation of Vav
affects its GEF activity. Under similar reaction conditions, the
Ran GTPase and the human H-ras protein failed to bind each
of the Vav fragments (with [data not shown] or without [Fig. 3]
Lck-phosphorylation) tested here.
In vitro Vav promotes GDP release from CDC42Hs-related
GTPases.We tested whether Vav could promote GDP release
from CDC42Hs, Rac1, and RhoA. For this purpose, GST
fusions of CDC42Hs, Rac1, and RhoA proteins bound to
[3H]GDP were incubated with either His6-Vav(DH), Lck-
phosphorylated His6-Vav(DH), His6-Vav(L), Lck-phosphory-
lated His6-Vav(L), or Ni-agarose alone. After 15 min of in-
cubation, the stimulation of GDP release (relative to the
Ni-agarose control) was determined. GDP release from
CDC42Hs was accelerated by each of the fragments of Vav
tested, although Vav(L) was more potent than Vav(DH), and
Lck-phosphorylation of Vav(L) enhanced its activity (Fig. 4).
Stimulation of GDP release from Rac1 was observed only with
Lck-phosphorylated Vav(L), while acceleration of GDP re-
lease from RhoA was observed with Lck-phosphorylated
Vav(DH) and Lck-phosphorylated Vav(L) (Fig. 4). In similar
reactions using H-Ras–GDP as the substrate, no acceleration
of GDP release was observed (data not shown). Taken to-
gether, these results suggest that Vav is a GEF for the Rho
family of GTPases and that the Dbl homology domain of Vav
is responsible for this activity.
Vav induces filopodium formation when used to transfect
REF-52 fibroblasts. We predicted that Vav might induce phe-
notypes in fibroblasts consistent with activation of one of the
members of the Rho family of GTPases (38). In fibroblasts,
Rac proteins have been shown to induce actin polymerization
at the plasma membrane to form membrane ruffles and lamel-
lipodia followed by the formation of stress fibers (27). The
stress fiber formation occurs in a RhoA-dependent manner
(27). More recently, a third member of the Rho family, human
CDC42 (CDC42Hs), has been shown to trigger the formation
of filopodia followed by induction of lamellipodia and stress
fibers (34). To test whether Vav affects cytoskeletal reorgani-
FIG. 3. Binding of Vav protein to CDC42, Rac1, or RhoA proteins. Fifty
picomoles of His6-Vav(DH) or His6-Vav(L) bound to nickel-agarose beads was
incubated with 500 pmol of the GST fusions of the indicated GTPase (CDC42Hs,
Rac1, RhoA, Ran, or H-ras) in their nucleotide-free state, GDP-bound state, or
GTP-bound state. All incubations were carried out for 1 h at room temperature
in 300 ml of buffer A containing 5 mM imidazole and 500 mg of BSA per ml.
Where indicated, the Vav protein was preincubated with the Lck kinase under
conditions where saturation of phosphorylation was achieved. For a negative
control, nickel-agarose beads not complexed with Vav protein were used in
similar reactions. After the incubation period, the nickel-agarose beads were
washed five times to remove material not bound to the beads and the resulting
pellets were analyzed by immunoblotting with antibodies specific for GST protein.
FIG. 4. Vav stimulates release of GDP from CDC42Hs, Rac1, and RhoA.
Forty picomoles of the indicated GTPase (CDC42Hs, Rac1, or RhoA) bound
with [3H]GDP was incubated with 10 pmol of His6-Vav(DH) or His6-Vav(L) or
without addition of Vav protein. Where indicated, the Vav proteins were pre-
incubated with Lck kinase under conditions where saturation of phosphorylation
of Vav was achieved. All reactions were carried out in 200 ml of buffer A
containing 1 mM GTP. After 15 min incubation, the amount of [3H]GDP re-
maining bound to the GTPases was determined by a nitrocellulose filter binding
assay. The values shown for percentage of GDP released reflect the percentage
of nucleotide released in the reaction mixture containing Vav relative to the
negative-control reaction mixtures (i.e., without Vav). They were calculated as
follows: % GDP release 5 [(cpm released in the presence of Vav) 2 (cpm
released in the absence of Vav)]/initial cpm of [3H]GDP bound to the GTPases.
In all experiments, the counts per minute (cpm) of [3H]GDP released from the
GTPases in the absence of Vav was less than 20% of the amount bound at time
zero. The values shown are the averages of duplicate data points which did not
differ by more than 8%. Similar results were obtained from three independent
experiments.
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zation at the plasma membrane, we transfected oncogenic Vav
into REF-52 fibroblasts and monitored for one of the cytoskel-
etal-reorganization phenotypes, namely, filopodium formation.
Figure 5A shows multiple filopodia projecting from a fibroblast
which stained positive for the Vav protein but not from fibro-
blasts lacking exogenous Vav expression. The formation of
filopodia in the Vav-transfected fibroblast is consistent with
our proposal that Vav is a GEF for the Rho/Rac/CDC42Hs
family of GTPases. We are currently examining whether Vav
affects lamellipodium and stress fiber formation.
Coexpression of Lck synergistically enhances Vav but not
Dbl or RhoA transforming activity. Our in vitro analysis sug-
gested that Lck phosphorylation of Vav enhanced its GEF
activity. Since we previously showed that the Vav-induced
transformed phenotype was consistent with the activation of
Rho proteins (24, 25), we evaluated the possibility that Lck
would enhance Vav transforming activity. We find that coex-
pression of activated Lck caused a 10-fold enhancement of Vav
focus-forming activity (Fig. 6 and 7). In contrast, Lck failed to
enhance the Dbl (Fig. 6) or Rho (Fig. 7) focus-forming activity.
These results suggest that Lck phosphorylation of Vav pro-
motes its Rho GEF activity, which in turn mediates its trans-
forming activity.
An alternate explanation for the synergistic transforming
activity seen when Lck is coexpressed with Vav is that Lck and
Vav show cooperation by activating parallel but otherwise in-
dependent signaling pathways. For example, we and others
recently showed that coexpression of activated RhoA or Rac
with activated Raf-1 caused a synergistic transforming activity
FIG. 5. Vav induces filopodium formation in fibroblasts. Rat embryo fibro-
blasts (REF-52) were grown to 80% confluence in Dulbecco’s modified Eagle’s
medium with 10% fetal bovine serum and transfected with 1 mg of total DNA per
60-mm-diameter dish (13, 41). A vector expressing a T7-tagged oncogenic Vav
(residues 66 through 845) was constructed and used for this purpose. Sixteen
hours after transfection, the cells were prepared for immunofluorescence and
light microscopy (34). (A) Filamentous actin was visualized with fluorescein
isothiocyanate-phalloidin. (B) Cells expressing Vav were identified by use of the
T7 tag, which was visualized with anti-T7 antibody (Novagen) and rhodamine-
conjugated goat anti-mouse secondary antibody (Molecular Probes).
FIG. 6. Coexpression of activated Lck(505F) caused synergistic enhance-
ment of Vav, but not Dbl, focus-forming activity. Cotransfection focus formation
analyses were done as described in Materials and Methods. (A) Data are the
averages of four dishes for each determination and are representative of two
independent assays. (B) Representative dishes were stained with crystal violet to
better visualize transformed foci.
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that was more than 10-fold above their additive focus-forming
potentials (25, 36). However, the inability of Lck to cause
synergistic enhancement of activated Dbl or RhoA argues
against this possibility (Fig. 6 and 7). Finally, we observed that
activated Lck alone caused the appearance of transformed foci
that were indistinguishable from those caused by Vav or Dbl
(data not shown) but different from those caused by activated
Ras or Raf. These transformation data are consistent with our
genetic and biochemical data and further support a Rho GEF
function for Vav.
Vav activates Rho-associated signaling events. Recent stud-
ies have shown that Rac1 and CDC42Hs, as well as Dbl, are
activators of Jnk (10, 31). Jnk in turn phosphorylates and
activates the Jun ATF-2 transcription factors (17). Addition-
ally, RhoA, Rac1, and CDC42Hs cause activation of the serum
response factor (20). Thus, in addition to causing changes in
actin organization, activation of Rho proteins may promote
changes in gene expression via upregulation of transcription
factor function. Our observation that Vav functions as a Rho
family GEF suggests that Vav should also modulate the activ-
ities of Jnk and the ATF-2 transcription factor. We observe
that oncogenic Vav, but not wild-type Vav, results in a more-
than-twofold activation of both Jnk and ATF-2 activities in
transient-transfection analyses of COS and NIH 3T3 cells
(data not shown).
DISCUSSION
We have examined the ability of Vav to serve as a GEF for
the Rho/Rac/CDC42 family members, using several distinct
biological and biochemical assays to assess the regulation of
these GTPases. These assays either directly or indirectly mea-
sure the ability of Vav to interact with and activate Rho/Rac/
CDC42-related GTPases. From each of these distinct assays
we have obtained evidence supporting our conclusion that Vav
is a GEF for Rho/Rac/CDC42-related GTPases. Further, these
studies raise several new questions concerning signaling of Vav
and other Dbl-related molecules.
The yeast Dbl homolog encoded by CDC24 has been dem-
onstrated to act as a GEF for the yeast CDC42 (49). The yeast
CDC42, like its mammalian counterpart, regulates cytoskeletal
reorganization (50). CDC42 is activated by the CDC24-GEF,
and the activated CDC42 in turn transmits its signal (at least in
part) through the downstream target, the PAK1 kinase (28).
Recently, a mammalian PAK1 has been shown to be a down-
stream target of CDC42 in vertebrates (48). We demonstrate
that Vav is functionally homologous to the CDC24-GEF by
showing the ability of fragments of Vav to complement a cdc24
temperature-sensitive defect in yeast. We observed several
fragments of Vav, each with an intact Dbl homology domain,
showing biological activity. First, full-length Vav in the pres-
ence of the Lck kinases is a potent suppressor of the loss of
CDC24 function (Fig. 2). Second, a fragment of Vav lacking
the N-terminal 66 amino acids as well as a fragment of Vav
encompassing the Dbl homology domain suppresses the loss of
CDC24 function (Fig. 2). In contrast, each of these biologically
active fragments of Vav failed to suppress the loss of CDC42
function, thus indicating that Vav likely functions upstream of
CDC42.
Recently, we have obtained additional genetic data support-
ing a role for Vav as a regulator of CDC42 function. We have
identified several mutants of Vav which, when expressed in
yeast, are lethal (17a). We compared the terminal lethal phe-
notypes of these dominant lethal mutants with the lethal phe-
notypes previously reported as blocking CDC42 function and
producing constitutive activation of CDC42. Loss of CDC42
function is lethal with an unbudded, large-cell phenotype (50).
In contrast, constitutive activation of CDC42 function leads to
a terminal lethal phenotype characterized by elongated buds
and to a multibudded phenotype (50). Interestingly, each of
the Vav lethal mutants exhibited one of these two distinct
phenotypes, one of which is indistinguishable from that of the
loss of CDC42 function and one of which is indistinguishable
from that of the gain of CDC42 function. Thus, these dominant
lethal Vav mutants likely represent two distinct classes of mu-
tants: one class of dominant interfering mutants which block
CDC42 function and a second class of dominant lethal mutants
which enhance CDC42 function. The lethality of the first type,
the dominant interfering mutants, can be suppressed by over-
expression of wild-type CDC42, indicating that these Vav mu-
tants block CDC42 function by sequestering available CDC42
in the cell.
From the genetic analysis of Vav in yeast, we conclude that
Vav has the potential to activate the CDC42 pathway. In con-
trast, from our yeast genetics analysis, we fail to find any
evidence that Vav activates Ras function in yeast (unpublished
data). The yeast genetics results suggest Vav is a GEF for
CDC42-like molecules. However, to assess the significance of
FIG. 7. Coexpression of activated Lck(505F) caused synergistic enhance-
ment of Vav, but not RhoA, focus-forming activity. Cotransfection focus forma-
tion analyses were done as described in Materials and Methods. (A) Data shown
are the averages of four dishes for each determination and are representative of
two independent assays. (B) Representative dishes were stained with crystal
violet to better visualize transformed foci.
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these observations for Vav function in animal cells, we sought
to characterize Vav using additional assays for Vav function.
The biochemistry of GEFs has revealed that they exhibit
specificity for a subset of small GTPases. GEFs functionally
related to the yeast CDC25 GEF catalyze nucleotide exchange
on Ras but not on other small GTPases (3). Similarly, the
Dbl-GEF catalyzes nucleotide exchange on CDC42-related
GTPases but not on Ras (18). Another biochemical character-
istic of GEFs is their preferential binding to nucleotide-free
GTPases rather than to GDP- or GTP-bound versions of the
GTPases (32). We observed several fragments of Vav, each
containing a complete Dbl homology domain, exhibiting GEF
activity directed towards Rho, Rac, and CDC42. In contrast,
these fragments of Vav lack the ability to catalyze nucleotide
exchange on the Ras or Ran GTPases.
We note that the GEF activity of Vav directed towards
RhoA and Rac1 is strictly dependent on Vav being phosphor-
ylated by the Lck kinase. CDC42 serves as a substrate for both
unphosphorylated and phosphorylated Vav, although phos-
phorylated Vav is the more potent GEF. The ability of Lck to
modulate Vav activity is significant in several respects. First,
Vav has been reported to be a substrate of Lck, and both of
these molecules are expressed in similar cell types (14). Sec-
ond, Lck appears to activate wild-type Vav expressed in yeast,
as indicated by the ability of wild-type Vav coexpressed with
Lck, but not wild-type Vav or Lck alone, to suppress cdc24ts.
Third, the in vitro GEF activity of Vav fragments directed
towards RhoA and Rac1 is strictly dependent on Vav being
phosphorylated by Lck. Taken together, these observations
lead us to suggest that Lck is an activator of Vav GEF activity.
To our knowledge, this represents the first known mechanism
for the activation of the GEF activity of a Dbl-related GEF.
We are currently examining whether other src-related tyrosine
kinases activate Vav’s GEF activity or the GEF activity of
other Dbl-related molecules. In this regard, we observe that
Lck and Dbl do not cooperate in transformation of fibroblasts
whereas Vav and Lck act synergistically in transformation of
fibroblasts. This may reflect the ability of Lck to activate Vav
but not Dbl.
Under conditions where Vav binds to Rho, Rac, and CDC42
GTPases, Vav fails to bind Ras or Ran. Vav binds preferen-
tially to nucleotide-free CDC42 and Rac1. In contrast, Vav
binds equally well to nucleotide-free or nucleotide-bound
RhoA. However, when Vav is phosphorylated by Lck, it binds
preferentially to nucleotide-free RhoA. The preferential bind-
ing of Vav to these GTPases is reminiscent of other GEFs
which preferentially bind to the reaction intermediate in the
nucleotide exchange reaction, i.e., nucleotide-free GTPase.
The biochemical characterization of Vav thus yields results
consistent with our yeast genetic studies, indicating that Vav is
an activator of CDC42-like GTPases. Further, both the yeast
genetic data and in vitro biochemical analysis of Vav indicate
that Lck phosphorylation of Vav enhances its GEF activity
directed towards CDC42-like GTPases. We are currently map-
ping phosphorylation sites in Vav to better understand the
involvement of Lck in the Vav signaling pathway.
While the yeast genetic analysis and in vitro biochemical
analysis of Vav strongly suggest that Vav is a GEF for CDC42-
related GTPases, these experimental approaches are not well
suited for evaluating signaling occurring in animal cells. The
mammalian CDC42/Rac/Rho pathways are known to induce
cytoskeletal changes as well as changes in gene expression. We
present several lines of evidence suggesting that Vav activates
CDC42/Rac/Rho signaling in animal cells. First, Vav induces
filopodium formation when transfected into REF-52 fibro-
blasts. Filopodium formation is known to be triggered by ac-
tivation of CDC42 (34). It will be interesting to determine
whether Vav also regulates other cytoskeletal-mediated events
such as membrane ruffling, stress fiber formation, and lamel-
lipodium formation. Second, Rac1 and CDC42 are activators
of the Jun nuclear kinase (10, 31). We observed that oncogenic
Vav activates Jun nuclear kinases. Third, Rac1 and CDC42
indirectly lead to the activation of the ATF-2 transcription
factor (17, 20). We observed that Vav also activates ATF-2 in
transient transfections. Thus, in each of these cell biological
assays for CDC42/Rac/Rho signaling we found evidence indi-
cating that Vav also has the potential to regulate these events.
From results obtained from any one of the experimental
approaches we employed to assess Vav’s involvement in Rho/
Rac/CDC42 signaling, we cannot make a compelling case for
Vav being a GEF for these GTPases. Taken together, the four
distinct lines of evidence presented here strongly suggest that
the physiological role of Vav is to activate Rho/Rac/CDC42-
related GTPases and that the Lck kinase modulates Vav ac-
tivity.
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